查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701282

急性骨髓性白血病治療市場規模、佔有率、趨勢分析報告：按疾病、治療、給藥途徑、最終用途、地區和細分市場進行預測，2025 年至 2030 年

Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模和趨勢

預計2024年全球急性骨髓性白血病治療市場規模為34.7億美元，2025年至2030年複合年成長率為10.6%。

急性骨髓性白血病發病率的上升和對先進治療的需求的不斷成長是由於基因突變、不健康的生活方式、持續接觸苯等有害化學物質以及輻射暴露等因素造成的。此外，老齡人口的增加和未滿足的需求的增加預計將進一步推動市場成長。

急性骨髓性白血病（AML）治療的進展迄今一直處於標靶治療進展的前沿。最近的趨勢包括 BCL2 抑制劑、IDH 抑制劑和 FLT3 抑制劑的重大發展。這些治療方法針對特定的基因突變提供個人化的治療方案，進而改善患者的治療效果。例如，對於新診斷的 FLT3-ITD 陽性急性骨髓性白血病患者，FDA 於 2023 年 7 月在美國核准了quizartinib（Vanflita），為標準化療提供了額外的治療選擇。

將Venetoclax與Azacitidine和其他甲基轉移酶抑制劑聯合治療，已顯示出提高 AML 患者存活率的良好效果。此外，研究也致力於將Venetoclax納入傳統的7+3化療方案中，以最大限度地提高治療效果。這些創新方法顯示人們越來越致力於開發多方面的治療策略，以改善患者的治療效果。

此外，包括 CAR-T 細胞療法在內的免疫療法趨勢代表了 AML 治療的改變趨勢。這些治療方法旨在增強免疫系統對癌細胞的反應，為選擇有限的患者帶來新的希望。對 AML 相關基因改變的深入了解帶來了進一步的個人化治療策略，例如使用 menin 抑制劑針對 KMT2A 和 NPM1 中的特定突變。

由於基因突變、不良生活習慣和環境危害等因素導致 AML 發病率不斷上升，凸顯了對創新治療方法的迫切需求。根據美國癌症協會估計，2025 年將有約 22,010 人被診斷出患有 AML，這進一步凸顯了對有效治療方案日益成長的需求。 2023年12月，蒙特婁大學的科學家獲得加拿大基因組組織600萬美元的津貼，用於為高急性骨髓性白血病患者開發一種新型細胞週期細胞週期蛋白K分解劑。針對高風險患者的創新治療方法的開發以及全球對研發的大量投資預計將推動市場成長。此外，製藥公司和研究機構之間的合作正在加快開發新的 AML 治療方法的步伐。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章急性骨髓性白血病治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
  • 管道分析

第4章急性骨髓性白血病治療市場：疾病業務分析

  • 2024年及2030年的疾病市場佔有率
  • 疾病細分儀表板
  • 市場規模、預測與趨勢分析（按治療，2018-2030 年）
  • 骨髓性白血病
  • 粒單核細胞白血病
  • 早幼粒細胞白血病
  • 單核細胞白血病
  • 其他

第5章急性骨髓性白血病治療市場：治療業務分析

  • 2024年和2030年的治療市場佔有率
  • 治療細分儀表板
  • 市場規模、預測與趨勢分析（按治療，2018-2030 年）
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第6章急性骨髓性白血病治療市場：給藥途徑業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 給藥途徑細分儀表板
  • 按管理路線分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 腸外
  • 口服

第7章急性骨髓性白血病治療市場：最終用途業務分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 最終用途細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院和診所
  • 專業中心
  • 居家照護環境
  • 門診治療中心

第8章急性骨髓性白血病治療市場：區域、估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年各國情況
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 2018-2030年各國情況
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030年各國情況
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年各國情況
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • DAIICHI SANKYO COMPANY, LIMITED
    • Jazz Pharmaceuticals plc
    • Novartis AG
    • Otsuka Pharmaceuticals Co.,Ltd.
    • Pfizer Inc.
    • Rigel Pharmaceuticals, Inc.
    • Merck KGaA
    • Sanofi
Product Code: GVR-4-68040-384-0

Market Size & Trends:

The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to grow at a CAGR of 10.6% from 2025 to 2030. Rising incidences of acute myeloid leukemia and increasing need for advanced therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost market growth further.

Advancements in targeted therapies have been at the forefront of the progress in Acute Myeloid Leukemia (AML) treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the U.S., enhancing treatment options alongside standard chemotherapy.

Combinations such as venetoclax with azacitidine or other hypomethylating agents have shown promising results in enhancing survival rates for AML patients. Additional research interest focuses on incorporating venetoclax into the traditional 7+3 chemotherapy regimen, which aims to maximize treatment efficacy. Such innovative approaches indicate a growing commitment to developing multifaceted treatment strategies that promise to improve patient outcomes.

Moreover, the exploration of immunotherapies, including CAR-T cell therapies, represents a transformative trend in AML treatment. These therapies are designed to bolster the immune system's response to cancer cells, thus providing new hope for patients who have limited options. The advancements in the understanding of genetic mutations associated with AML have further contributed to personalized treatment strategies, such as targeting specific mutations such as KMT2A and NPM1 with menin inhibitors.

The growing incidence of AML, driven by factors such as genetic mutations, unhealthy lifestyles, and environmental hazards, underscores the urgent need for innovative therapies. According to the American Cancer Society, approximately 22,010 individuals are estimated to be diagnosed with AML in 2025, further highlighting the rising demand for effective treatment options. In December 2023, scientists at the University of Montreal secured a USD 6 million grant from Genome Canada to develop a novel Cyclin K degrader for high-risk acute myeloid leukemia patients, aiming to enhance treatment outcomes and stimulate economic growth in Canada. The development of innovative therapies for high-risk patients, along with substantial global investments in research and development, is expected to drive market growth. Furthermore, partnerships between pharmaceutical companies and research institutions are enhancing the pace of new AML treatment development.

Global Acute Myeloid Leukemia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end use, and region:

  • Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Myeloblastic Leukemia
  • Myelomonocytic Leukemia
  • Promyelocytic Leukemia
  • Monocytic Leukemia
  • Other Diseases
  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)
  • Chemotherapy
    • Anti-metabolites
    • Alkylating Agents
    • Anthracycline Drugs
    • Others
  • Targeted Therapy
    • FLT3 Inhibitors
    • Rydapt
    • Vanflyta
    • Xospata
    • IDH Inhibitors
    • Tibsovo
    • Rezlidhia
    • Idhifa
    • Mylotarg
    • BCL-2 Inhibitor
    • Hedgehog Pathway Inhibitor
  • Immunotherapy
    • Bispecific Antibodies
    • Antibody-drug Conjugates
    • Immune Checkpoint Inhibitors
    • Chimeric Antigen Receptor (CAR) T-cell Therapy
  • Other Treatments
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Parenteral
  • Oral
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals and Clinics
  • Specialty Centers
  • Homecare Setting
  • Ambulatory Care Centers
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2030
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Myeloblastic Leukemia
    • 4.4.1. Myeloblastic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.5. Myelomonocytic Leukemia
    • 4.5.1. Myelomonocytic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.6. Promyelocytic Leukemia
    • 4.6.1. Promyelocytic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.7. Monocytic Leukemia
    • 4.7.1. Monocytic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.8. Other Diseases
    • 4.8.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
    • 5.4.2. Anti-metabolites
    • 5.4.3. Anti-metabolites Market, 2018 - 2030 (USD Million)
    • 5.4.4. Alkylating Agents
    • 5.4.5. Alkylating Agents Market, 2018 - 2030 (USD Million)
    • 5.4.6. Anthracycline Drugs
    • 5.4.7. Anthracycline Drugs Market, 2018 - 2030 (USD Million)
    • 5.4.8. Others
    • 5.4.9. Others Market, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
    • 5.5.2. FLT3 Inhibitors
    • 5.5.3. FLT3 Inhibitors Market, 2018 - 2030 (USD Million)
      • 5.5.3.1. Rydapt
        • 5.5.3.1.1. Rydapt Market, 2018 - 2030 (USD Million)
      • 5.5.3.2. Vanflyta
        • 5.5.3.2.1. Vanflyta Market, 2018 - 2030 (USD Million)
      • 5.5.3.3. Xospata
        • 5.5.3.3.1. Xospata Market, 2018 - 2030 (USD Million)
    • 5.5.4. IDH Inhibitors
    • 5.5.5. IDH Inhibitors Market, 2018 - 2030 (USD Million)
      • 5.5.5.1. Tibsovo
        • 5.5.5.1.1. Tibsovo Market, 2018 - 2030 (USD Million)
      • 5.5.5.2. Rezlidhia
        • 5.5.5.2.1. Rezlidhia Market, 2018 - 2030 (USD Million)
      • 5.5.5.3. Idhifa
        • 5.5.5.3.1. Idhifa Market, 2018 - 2030 (USD Million)
    • 5.5.6. Mylotarg
      • 5.5.6.1. Mylotarg Market, 2018 - 2030 (USD Million)
    • 5.5.7. BCL-2 Inhibitor
      • 5.5.7.1. BCL-2 Inhibitor Market, 2018 - 2030 (USD Million)
    • 5.5.8. Hedgehog Pathway Inhibitor
      • 5.5.8.1. Hedgehog Pathway Inhibitor Market, 2018 - 2030 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
    • 5.6.2. Bispecific Antibodies
      • 5.6.2.1. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.6.3. Antibody-drug Conjugates
      • 5.6.3.1. Antibody-drug Conjugates Market, 2018 - 2030 (USD Million)
    • 5.6.4. Immune Checkpoint Inhibitors
      • 5.6.4.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
    • 5.6.5. Chimeric Antigen Receptor (CAR) T-cell Therapy
      • 5.6.5.1. Chimeric Antigen Receptor (CAR) T-cell Therapy Market, 2018 - 2030 (USD Million)
  • 5.7. Other Treatments
    • 5.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals and Clinics
    • 7.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Centers
    • 7.5.1. Specialty Centers Market, 2018 - 2030 (USD Million)
  • 7.6. Homecare Setting
    • 7.6.1. Homecare Setting Market, 2018 - 2030 (USD Million)
  • 7.7. Ambulatory Care Centers
    • 7.7.1. Ambulatory Care Centers Market, 2018 - 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Astellas Pharma Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Bristol-Myers Squibb Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. DAIICHI SANKYO COMPANY, LIMITED
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Jazz Pharmaceuticals plc
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Novartis AG
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Otsuka Pharmaceuticals Co.,Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Pfizer Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Rigel Pharmaceuticals, Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Merck KGaA
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Sanofi
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 5. Global acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6. Global acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7. Global acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 8. North America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 10. North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 11. North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12. North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 13. U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 14. U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15. U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16. U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 17. Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 18. Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19. Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 21. Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 22. Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23. Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 25. Europe acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 27. Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 28. Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29. Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30. UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 31. UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32. UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33. UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 34. Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 35. Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36. Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 38. France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 39. France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40. France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 42. Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 43. Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44. Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 46. Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 47. Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48. Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50. Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 51. Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 52. Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53. Denmark acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54. Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 55. Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56. Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57. Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 58. Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 59. Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60. Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 67. China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 68. China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 69. China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70. China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 71. Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 72. Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 73. Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74. Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 75. India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 76. India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 77. India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78. India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 80. Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 81. Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82. Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 83. South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 84. South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 85. South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86. South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 87. Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 88. Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 89. Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90. Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 91. Latin America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 92. Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 93. Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 94. Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95. Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 96. Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 97. Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 98. Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99. Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 100. Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 101. Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 102. Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103. Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 109. South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 110. South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 111. South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 112. South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 117. UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 118. UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 119. UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 120. UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 121. Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 122. Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 123. Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 124. Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Acute myeloid leukemia treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and route of administration outlook (USD Million)
  • Fig. 10 End use outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Acute myeloid leukemia treatment market dynamics
  • Fig. 13 Acute myeloid leukemia treatment market: Porter's five forces analysis
  • Fig. 14 Acute myeloid leukemia treatment market: PESTLE analysis
  • Fig. 15 Acute myeloid leukemia treatment market: Disease segment dashboard
  • Fig. 16 Acute myeloid leukemia treatment market: Disease market share analysis, 2024 & 2030
  • Fig. 17 Myeloblastic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 18 Myelomonocytic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 19 Promyelocytic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 20 Monocytic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 21 Other diseases market, 2018 - 2030 (USD Million)
  • Fig. 22 Acute myeloid leukemia treatment market: Treatment segment dashboard
  • Fig. 23 Acute myeloid leukemia treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 24 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Anti-metabolites market, 2018 - 2030 (USD Million)
  • Fig. 26 Alkylating agents market, 2018 - 2030 (USD Million)
  • Fig. 27 Anthracycline drugs market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 30 FLT3 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 31 Rydapt market, 2018 - 2030 (USD Million)
  • Fig. 32 Vanflyta market, 2018 - 2030 (USD Million)
  • Fig. 33 Xospata market, 2018 - 2030 (USD Million)
  • Fig. 34 IDH inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 35 Tibsovo market, 2018 - 2030 (USD Million)
  • Fig. 36 Rezlidhia market, 2018 - 2030 (USD Million)
  • Fig. 37 Idhifa market, 2018 - 2030 (USD Million)
  • Fig. 38 Mylotarg market, 2018 - 2030 (USD Million)
  • Fig. 39 BCL-2 inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 40 Hedgehog pathway inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 41 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 42 Bispecific antibodies market, 2018 - 2030 (USD Million)
  • Fig. 43 Antibody-drug conjugates market, 2018 - 2030 (USD Million)
  • Fig. 44 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 45 Chimeric Antigen Receptor (CAR) T-cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 46 Other treatments market, 2018 - 2030 (USD Million)
  • Fig. 47 Acute myeloid leukemia treatment market: Route of administration segment dashboard
  • Fig. 48 Acute myeloid leukemia treatment market: Route of administration market share analysis, 2024 & 2030
  • Fig. 49 Parenteral market, 2018 - 2030 (USD Million)
  • Fig. 50 Oral market, 2018 - 2030 (USD Million)
  • Fig. 51 Acute myeloid leukemia treatment market: End use segment dashboard
  • Fig. 52 Acute myeloid leukemia treatment market: End use market share analysis, 2024 & 2030
  • Fig. 53 Hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 54 Specialty centers market, 2018 - 2030 (USD Million)
  • Fig. 55 Homecare setting market, 2018 - 2030 (USD Million)
  • Fig. 56 Ambulatory care centers market, 2018 - 2030 (USD Million)
  • Fig. 57 Acute myeloid leukemia treatment market revenue, by region
  • Fig. 58 Regional marketplace: Key takeaways
  • Fig. 59 Regional marketplace: Key takeaways
  • Fig. 60 North America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 U.S. country dynamics
  • Fig. 62 U.S. acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Canada country dynamics
  • Fig. 64 Canada acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Mexico country dynamics
  • Fig. 66 Mexico acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Europe acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 UK country dynamics
  • Fig. 69 UK acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Germany country dynamics
  • Fig. 71 Germany acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 France country dynamics
  • Fig. 73 France acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Italy country dynamics
  • Fig. 75 Italy acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Spain country dynamics
  • Fig. 77 Spain acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Norway country dynamics
  • Fig. 79 Norway acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 Sweden country dynamics
  • Fig. 81 Sweden acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Denmark country dynamics
  • Fig. 83 Denmark acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Japan country dynamics
  • Fig. 86 Japan acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 China country dynamics
  • Fig. 88 China acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 89 India country dynamics
  • Fig. 90 India acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 91 Australia country dynamics
  • Fig. 92 Australia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 93 South Korea country dynamics
  • Fig. 94 South Korea acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 95 Thailand country dynamics
  • Fig. 96 Thailand acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 97 Latin America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 98 Brazil country dynamics
  • Fig. 99 Brazil acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 100 Argentina country dynamics
  • Fig. 101 Argentina acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 102 MEA acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 103 South Africa country dynamics
  • Fig. 104 South Africa acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 105 Saudi Arabia country dynamics
  • Fig. 106 Saudi Arabia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 107 UAE country dynamics
  • Fig. 108 UAE acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 109 Kuwait country dynamics
  • Fig. 110 Kuwait acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 111 Company categorization
  • Fig. 112 Company market position analysis
  • Fig. 113 Strategic framework